Roberto M. Lemoli
A5009267255- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Tryptophan and brain disorders
- Adenosine and Purinergic Signaling
- Mesenchymal stem cell research
- Eosinophilic Disorders and Syndromes
- Neutropenia and Cancer Infections
- Liver physiology and pathology
- Hemoglobinopathies and Related Disorders
- Protein Degradation and Inhibitors
- Toxin Mechanisms and Immunotoxins
- Platelet Disorders and Treatments
- RNA Interference and Gene Delivery
- Phagocytosis and Immune Regulation
University of Genoa
2016-2025
Ospedale Policlinico San Martino
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2001-2022
Fondazione Gimema Onlus
2020
Policlinico S.Orsola-Malpighi
2006-2019
Italian Foundation of Myelodysplastic Syndromes
2019
University of Bologna
2007-2018
John Wiley & Sons (United States)
2016
Alleanza Contro il Cancro
2001-2015
Istituti Ospitalieri di Cremona
2012-2013
Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in previous phase 1b study.
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Abstract Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients Methods: Data were pooled from enrolled in a phase III study (NCT02993523) that compared treated or placebo prior Ib (NCT02203773) where azacitidine. Enrolled ineligible for intensive therapy due to age ≥75 years and/or comorbidities. on received 400 mg orally (days 1–28) (75 mg/m2; days 1–7/28-day cycle). Results: In the...
Severely immunocompromised patients are at risk for prolonged or relapsed Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We aimed evaluate efficacy safety of combination treatment in COVID-19 patients.We included all with prolonged/relapsed treated therapy 2 antivirals (remdesivir plus nirmatrelvir/ritonavir, molnupiravir case renal failure) plus, if available, anti-spike monoclonal antibodies (mAbs), between February October 2022. The main outcomes were...
Abstract Venetoclax‐azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible intensive chemotherapy based on the interim overall survival (OS) analysis VIALE‐A study (NCT02993523). Here, long‐term follow‐up presented to address benefit and outcomes venetoclax‐azacitidine. Patients AML who were randomized 2:1 receive venetoclax‐azacitidine or placebo‐azacitidine. OS was primary endpoint; complete remission with/without blood count recovery...
Many lymphoma and myeloma patients fail to undergo ASCT owing poor mobilization. Identification of mobilizers (PMs) would provide a tool for early intervention with new mobilization agents. The Gruppo italianoTrapianto di Midollo Osseo working group proposed definition PMs applicable clinical trials practice. analytic hierarchy process, method decision making, was used in setting prioritized criteria. Lymphoma or were defined as 'proven PM' when: (1) after adequate (G-CSF 10 μg/kg if alone...
Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before receipt ruxolitinib may predict drug discontinuation in and reasons for discontinuation, phase at salvage therapies influence outcome. Methods A centralized electronic clinical database was created 20 European hematology centers, including laboratory data 524 who received myelofibrosis. Results At 3 years, 40.8% had...
In acute myeloid leukemia (AML), alloreactive natural killer (NK) cells are crucial mediators of immune responses after haploidentical stem cell transplantation. Allogeneic NK infusions have been adoptively transferred with promising clinical results. We aimed at determining whether the composition graft in terms frequency influence response a group elderly AML patients undergoing immunotherapy.Seventeen patients, first complete remission (CR; median age 64 years, range 53-73) received from...
Abstract It has been reported that ATP inhibits or stimulates lymphoid cell proliferation depending on the cellular subset analyzed. In this study, we show exerts strikingly opposite effects anti-CD3/CD28–activated and regulatory CD4+ T cells (Tregs), based nucleotide concentration. We demonstrate physiological concentrations of extracellular (1–50 nM) do not affect activated Tregs. Conversely, higher have a bimodal effect cells. Whereas 250 nM proliferation, cytokine release, expression...
Summary COVID‐19 is associated with high mortality in patients haematological malignancies (HM) and rate of seroconversion unknown. The ITA‐HEMA‐COV project (NCT04352556) investigated patterns for SARS‐CoV‐2 IgG HMs. A total 237 patients, PCR‐positive at least one test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid 54 (22·8%) plasma cell neoplasms. Overall, 69% (164 237) detectable serum antibodies. Serologically negative (31%, 73...
Summary Outcome of early treatment COVID‐19 with antivirals or anti‐spike monoclonal antibodies (MABs) in patients haematological malignancies (HM) is unknown. A retrospective study HM treated for mild/moderate between March 2021 and July 2022 was performed. The main composite end‐point failure (severe COVID‐19‐related death). We included 328 consecutive who received MABs ( n = 120, 37%; sotrovimab, 73) 208, 63%; nirmatrelvir/ritonavir, 116) over a median two days after symptoms started; 111...
Abstract Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared patients the myeloproliferative phenotype. Aims Methods Prognostic correlates of phenotype were explored in 886 ruxolitinib‐treated primary/secondary MF (PMF/SMF) included RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 10 9 /L and/or hemoglobin <11/<10 g/dL (males/females) platelets <100 /L. Results Overall, 407 (45.9%) had...
PURPOSE: To assess the clinical relevance of minimal residual disease (MRD) in patients with multiple myeloma (MM), 50 were monitored while they complete remission (CCR) after autologous or allogeneic stem-cell transplantation. PATIENTS AND METHODS: Stringent molecular monitoring using clonal markers based on rearranged immunoglobulin heavy-chain genes was performed 44 MM CCR. Molecular (MCR) defined as more than one consecutive negative polymerase chain reaction (PCR) test result. RESULTS:...
Viral-based techniques are the most efficient systems to deliver DNA into stem cells because they show high gene transduction and transgene expression in many cellular models. However, use of viral vectors has several disadvantages mainly involving safety risks. Conversely, nonviral methods rather inefficient for primary cells. The Nucleofector technology, a new electroporation-based transfer technique, proved be an tool transfecting hard-to-transfect cell lines little is known about...